Open AccessEffects of 5‐HT ₃ receptor antagonists on cisplatin‐induced kidney injury
Author(s) -
Goda Mitsuhiro,
Kanda Masaya,
Yoshioka Toshihiko,
Yoshida Ami,
Murai Yoichi,
Zamami Yoshito,
Aizawa Fuka,
Niimura Takahiro,
Hamano Hirofumi,
Okada Naoto,
Yagi Kenta,
Chuma Masayuki,
IzawaIshizawa Yuki,
Ishizawa Keisuke
Publication year - 2021
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.13045
Subject(s) - cisplatin , medicine , pharmacology , acute kidney injury , ondansetron , receptor antagonist , adverse effect , granisetron , vomiting , antagonist , receptor , chemotherapy , antiemetic
Nausea, vomiting, and renal injury are the common adverse effects associated with cisplatin. Cisplatin is excreted via the multidrug and toxin release (MATE) transporter, and the involvement of the MATE transporter in cisplatin‐induced kidney injury has been reported. The MATE transporter is also involved in the excretion of ondansetron, but the effects of 5‐HT 3 receptor antagonists used clinically for cisplatin‐induced renal injury have not been elucidated. Therefore, the aim of this study was to investigate the effects of 5‐HT 3 receptor antagonists in a mouse model of cisplatin‐induced kidney injury and to validate the results using medical big data analysis of more than 1.4 million reports and a survey of 3000 hospital medical records. The concomitant use of a first‐generation 5‐HT 3 receptor antagonist (ondansetron, granisetron, or ramosetron) significantly increased cisplatin accumulation in the kidneys and worsened renal damage. Conversely, the concomitant use of palonosetron had no effect on renal function compared with the use of cisplatin alone. Furthermore, an analysis of data from the US Food and Drug Administration Adverse Event Reporting System and retrospective medical records revealed that the combination treatment of cisplatin and a first‐generation 5‐HT 3 receptor antagonist significantly increased the number of reported renal adverse events compared with the combination treatment of cisplatin and a second‐generation 5‐HT 3 receptor antagonist. These results suggest that compared with the first‐generation antagonists, second‐generation 5‐HT 3 receptor antagonists do not worsen cisplatin‐induced acute kidney injury. The findings should be validated in a prospective controlled trial before implementation in clinical practice.